Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company dedicated to developing inhaled therapies for rare cardiopulmonary diseases.
Last updated September 1, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
Liquidia Corporation is a biopharmaceutical company focused on developing best-in-class therapies for rare cardiopulmonary diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company utilizes its proprietary PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines. Its pipeline includes L606, an investigational sustained-release liposomal formulation of treprostinil developed in partnership with Pharmosa Biopharm.
History
Liquidia Corporation is a biopharmaceutical company. It is dedicated to developing best-in-class therapies for rare cardiopulmonary diseases like pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company uses its proprietary PRINT® technology to enhance the efficacy, tolerability, and convenience of medicines. Its pipeline includes L606, an investigational sustained-release liposomal formulation of treprostinil developed in partnership with Pharmosa Biopharm.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/liquidia-corporation · Editorial policy · How profiles are compiled